loader2
Partner With Us NRI

Zydus Lifesciences Ltd share Price Today

Company details

1,040.40
1,067.75
498.85
1,172.50
6M Return 64.55%
1Y Return 105.63%
Mkt Cap.(Cr) 105,951.41
Volume 1,516,739
Div Yield 0.28%
OI
-
OI Chg %
-
Volume 1,516,739

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Decent performance; US pipeline, India traction key…
About The Stock

    Zydus is a leading pharma company with family pedigree having a presence in domestic branded formulations, US generics and is in the process of repurposing itself into niche areas of specialty pharmaceuticals, biosimilars and vaccines.

    • Q3FY23 revenue break-up – US: 46.3%, India: 29.6%, Wellness: 9.9%, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa: 14.2%
    • Zydus is the fourth largest pharma company in India with 14 brands among Top 300 pharma brands in India and nine with ₹ 100 crore+ sales
Q3FY23

    Zydus delivered good set of numbers, which beat our estimates.

    • Revenues grew 19.8% YoY at ₹ 4362 crore
    • EBITDA grew 27.2% YoY to ₹ 956 crore. EBITDA margins improved 127 bps YoY to 21.9%
    • Adjusted net profit rose 22.8% YoY to ₹ 622.5 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Zydus Lifesciences announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Revenue from operations was Rs 55,338 million, up 10% over last year.
  • Research & Development (R&D) investments for the quarter stood at Rs 3,516 million (6.4% of revenues).
  • EBITDA for the quarter was Rs 16,305 million, up 30% YoY. EBITDA margin for the quarter stood at 29.5%, an improvement of 440 bps on a YoY basis.
  • Net Profit for the quarter was Rs 11,823 million, up 299% YoY.
  • Capex (organic) for the quarter was Rs 2,126 million

FY24 Financial Highlights:

  • Revenue from operations was Rs 1,95,474 million, up 13% over last year.
  • Research & Development (R&D) investments stood at Rs 13,096 million (6.7% of revenues).
  • EBITDA was Rs 53,843 million, up 40% YoY. EBITDA margin stood at 27.5%, an improvement of 510 bps over the previous year.
  • Net Profit was Rs 38,595 million, up 97% YoY.
  • Capex (organic) for the year was Rs 8,628 million.
  • Net Debt to Equity ratio as on 31st March, 2024 was -0.04x while Net Debt to EBITDA stood at -0.16x at the end of March, 2024. Net Cash (negative Net Debt) as on March 31st, 2024 was Rs 8,561 million. 

Dr. Sharvil Patel, Managing Director, said, "We are happy to close the year on a strong note, driven by robust performance across our businesses. Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well. We aspire to sustain strong performance in fiscal year 2024-25 with strong revenue growth and strive to improve EBITDA margins further from FY24 levels. This strong performance is a testament to our commitment to creating long-term value for our stakeholders, and we are wellpositioned for future growth and innovation"

Result PDF

View Other Company Results

Zydus Lifesciences Ltd shares SWOT Analysis

Strengths (12)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth

Weakness (1)

  • MFs decreased their shareholding last quarter

Opportunity (2)

  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 1,067.0
R2 1,081.1
R3 1,094.4
Pivot

1,053.70

S1 1,039.7
S2 1,026.4
S3 1,012.3
EMA SMA
1,032.1
986.7
914.0
805.8
1,023.8
994.9
906.6
766.9
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
INTEGRATED CORE STRATEGIES (ASIA) PTE.LTD. Bulk Purchase 2019-05-28 258.21 5460159 NSE
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTF Bulk Purchase 2015-11-30 403 7102797 NSE
BLACKROCK FUNDS INTERNATIONAL OPPORTUNITIES PORTF Bulk Sell 2015-11-30 402.79 555000 NSE
Name Category Shares
Zydus Family Trust (Pankaj R. Patel, Pritiben P. Patel and Sharvil P. Patel-Trustees) PROMOTER 74.97%

OUR RESEARCH VIEW

Investment recommendation
Decent performance; US pipeline, India traction key…
Call Date
04 Feb 2023
Entry Price 430.00
Target Price 500.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Zydus Lifesciences Ltd Stocks COMPARISON

Financials( in Cr) Zydus Lifesciences Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Dr Reddys Laboratories Ltd
Price 1,052.95 1,464.90 1,479.45 4,392.10 5,965.30
% Change -0.52 -0.08 0.05 3.22 1.58
Mcap Cr 105,951.41 351,478.58 119,445.91 116,596.64 99,511.94
Revenue TTM Cr 17,237.40 43,885.68 15,790.60 7,767.51 24,669.70
Net Profit TTM Cr 1,997.30 8,560.84 2,513.47 1,823.38 4,507.30
PE TTM 27.42 35.12 28.05 72.85 17.81
1 Year Return 105.63 51.26 54.71 26.29 30.93
ROCE 16.25 16.79 14.76 19.30 25.99
ROE 14.05 16.46 10.66 14.89 21.21
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 17,515.80 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 39,096.78 -22,281.88
LAST 3M 109,317.46 -33,313.91
LAST 6M 173,877.04 36,325.60
LAST 12M 271,641.54 124,224.97
Zydus Lifesciences Limited - Press Release

May 24, 2024 l NSE Announcement

Zydus completes Phase II clinical study of NLRP3 inhibitor ¿Usnoflast (ZYIL1)`

May 24, 2024 l BSE Announcement

Zydus Lifesciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates

May 23, 2024 l NSE Announcement

Date Action Type Ratio
Jul 28, 2023 Dividend 600
Jul 28, 2022 Dividend 250

Zydus Lifesciences Ltd Information

Stock PE (TTM)
27.42
Promoter Holding
74.98%
Book Value
197.0667
ROCE
16.25%
ROE
14.05%
Registered Address

Zydus Corporate Park S No 536, Khoraj Sarkhej-Gandhinagar H/W, Ahmedabad, Gujarat, 382481

Tel : 91-079-26868100
Email : dhavalsoni:zyduscadila.com; upen.shah:zyduscadila.
Website : http://www.zyduscadila.com
Registrar

Sharepro Services India P Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 532321
NSE Code : ZYDUSLIFE
Book Closure Date (Month) :
BSE Group : A
ISIN : INE010B01027

FAQ’s on Zydus Lifesciences Ltd Shares

You can buy Zydus Lifesciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Zydus Lifesciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 28, 2024 03:55 PM the closing price of Zydus Lifesciences Ltd was Rs.1,052.95.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 28, 2024 03:55 PM, the market cap of Zydus Lifesciences Ltd stood at Rs. 105,951.41.

The latest PE ratio of Zydus Lifesciences Ltd as of May 28, 2024 03:55 PM is 27.42

The latest PB ratio of Zydus Lifesciences Ltd as of May 28, 2024 03:55 PM is 0.19

The 52-week high of Zydus Lifesciences Ltd share price is Rs. 1,172.50 while the 52-week low is Rs. 498.85

According to analyst recommendations, Zydus Lifesciences Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app